Novartis secures European approval for remibrutinib in chronic spontaneous urticaria
GSK secures US and EU fast-track designations for efimosfermin in MASH
Veradermics reports positive Phase 2/3 results for oral VDPHL01 in pattern hair loss treatment
Cantargia reports early remission data from nadunolimab trial in MDS and AML
AOTI reports strong real-world outcomes for TWO2 wound therapy
Ascletis completes enrolment for US Phase II study of ASC30 in diabetes